XOMA Royalty-backed XenoTherapeutics to acquire Repare Therapeutics.

XOMA Royalty-backed XenoTherapeutics, a not-for-profit research organization, agreed to acquire Repare Therapeutics, a clinical-stage precision oncology company. Financial terms were not disclosed. “The Transaction provides a cash payment to shareholders and the opportunity for continued participation in milestones and royalties from existing and potential future partnerships. On behalf of the Company, I would like to acknowledge and thank our employees for their dedication and exceptional service,” Steve Forte, Repare President, CEO, and CFO.